2-(2-amino-1,3-thiazol-5-yl)-N-(3-fluorophenyl)acetamide | 385785-31-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-amino-1,3-thiazol-5-yl)-N-(3-fluorophenyl)acetamide
• 英文别名: 2-(2-amino-1,3-thiazole-5-yl)-N-(3-fluorophenyl)acetamide；N-(3-fluorophenyl)-2-amino-1,3-thiazol-5-ylacetamide
• CAS: 385785-31-9
• 化学式: C₁₁H₁₀FN₃OS
• 分子量: 251.284
• InChiKey: GEALDWXXQCDVHB-UHFFFAOYSA-N

物化性质

• 沸点：
  518.6±40.0 °C(Predicted)
• 密度：
  1.457±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  96.2
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(2-amino-1,3-thiazol-5-yl)-N-(3-fluorophenyl)acetamide 在 溶剂黄146 、 potassium iodide 作用下， 以 N-甲基吡咯烷酮 、 N,N-二甲基乙酰胺 为溶剂， 反应 3.0h， 生成 N-(3-fluorophenyl)-2-{2-[(7-{3-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]propoxy}-6-methoxyquinazolin-4-yl)amino]-1,3-thiazol-5-yl}acetamide
  参考文献：
  名称：

  Discovery of Novel and Potent Thiazoloquinazolines as Selective Aurora A and B Kinase Inhibitors

  摘要：

  The synthesis of a novel series of quinazolines substituted at C4 by five-membered ring aminoheterocycles is reported. Their in vitro structure-activity relationships versus Aurora A and B serine-threonine kinases is discussed. Our results demonstrate that quinazolines with a substituted aminothiazole at C4 possess potent Aurora A and B inhibitory activity and excellent selectivity against a panel of various serine-threonine and tyrosine kinases, as exemplified by compound 46. We found also that the position and nature of the substituent on the thiazole play key roles in cellular potency. Compounds with an acetanilide substituent at C5' have the greatest cellular activity. The importance of the C5' position for substitution has been rationalized by ab initio molecular orbital calculations. Results show that the planar conformation with the sulfur of the thiazole next to the quinazoline N-3 is strongly favored over the other possible planar conformation. Compound 46 is a potent suppressor of the expression of phospho-histone H3 in tumor cells in vitro as well as in vivo, where 46, administered as its phosphate prodrug 54, suppresses the expression of phospho-histone H3 in subcutaneously implanted tumors in nude mice.

  DOI：

  10.1021/jm050786h
• 作为产物：
  描述：

  2-(2-氨基噻唑-5-基)乙酸乙酯 在 吡啶 、 盐酸 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.67h， 生成 2-(2-amino-1,3-thiazol-5-yl)-N-(3-fluorophenyl)acetamide
  参考文献：
  名称：

  [EN] TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS
  [FR] DÉRIVÉS DE TRIAZINE ET LEURS APPLICATIONS THÉRAPEUTIQUES

  摘要：

  本发明包括如式(I)所示的化合物及其药学上可接受的盐等。

  公开号：

  WO2010144338A1

文献信息

• [EN] QUINAZOLINE COMPOUNDS<br/>[FR] COMPOSES DE QUINAZOLINE
  申请人：ASTRAZENECA AB

  公开号：WO2004058752A1

  公开（公告）日：2004-07-15

  Quinazoline derivatives of formula (I) wherein A is 5-membered heteroaryl containing a sulphur atom and optionally containing one or more nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.

  式(I)中的喹唑啉衍生物，其中A是含有硫原子并且可选地含有一个或多个氮原子的5-成员杂芳基；含有它们的组合物，其制备方法以及它们在治疗中的用途。
• Substituted quinazoline derivatives and their use as inhibitors
  申请人：AstraZeneca AB

  公开号：US20030187002A1

  公开（公告）日：2003-10-02

  The use of a compound of formula (I) 1 or a salt, ester or amide thereof; where X is O, or S, S(O) or S(O) 2 , or NR 6 where R 6 is hydrogen or C 1-6 alkyl,; R 5 is an optionally substituted 5-membered heteroaromatic ring, R 1 , R 2 , R 3 , R 4 are independently selected from various specified moieties, in the preparation of a medicament for use in the inhibition of aurora 2 kinase. Certain compounds are novel and these, together with pharmaceutical compositions containing them are also described and claimed.

  使用式(I)的化合物或其盐、酯或酰胺； 其中X为O、S、S(O)或S(O)2，或NR6，其中R6为氢或C1-6烷基； R5为可选择取代的5-成员杂芳环， R1、R2、R3、R4分别选自各种指定的基团，在制备用于抑制aurora 2激酶的药物中使用。 某些化合物是新颖的，这些化合物以及含有它们的药物组合物也有描述和声明。
• Inhibitors of protein kinases
  申请人：Michaelides R. Michael

  公开号：US20070135387A1

  公开（公告）日：2007-06-14

  Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.

  揭示了抑制蛋白激酶的化合物、含有这些化合物的组合物以及利用这些化合物治疗疾病的方法。
• Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
  申请人：Gavai V. Ashvinikumar

  公开号：US20070004732A1

  公开（公告）日：2007-01-04

  The invention relates to at least one pyrrolotriazine derivative, at least one pharmaceutical composition comprising at least one pyrrolotriazine derivative, and at least one method of using at least one pyrrolotriazine derivative to treat at least one kinase associated condition.

  本发明涉及至少一种吡咯并三嗪衍生物，至少一种包含至少一种吡咯并三嗪衍生物的制药组合物，以及至少一种使用至少一种吡咯并三嗪衍生物治疗至少一种激酶相关疾病的方法。
• INHIBITORS OF PROTEIN KINASES
  申请人：Michaelides Michael R.

  公开号：US20090131425A1

  公开（公告）日：2009-05-21

  Compounds that inhibit Aurora-kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.

  本发明揭示了抑制极化激酶的化合物、含有该化合物的组合物以及使用该化合物治疗疾病的方法。